Clear impact
IN.PACTTM AV Access Trial
5 years safety follow-up data
now released
IN.PACTTM AdmiralTM† DCB for AV Fistula:
the proactive approach for AV Fistula maintenance in
end-stage renal disease (ESRD) patients.
Your browser is out of date
With an updated browser, you will have a better Medtronic web site experience. Update my browser now.
Sustained impact
The IN.PACT™ AV Access Trial confirms the superiority of IN.PACT™ DCB (Drug-Coated Balloon) vs PTA through 3 years2, showing safety profile through 5 years.3
Watch Dr. Holden present the IN.PACT™ AV Access Trial 5 year data at Charing Cross.
Proven impact
The first and only DCB trial in AVF to meet primary effectiveness and safety endpoints. See the manuscript published on the New England Journal of Medicine.
Fewer reinterventions than PTA1 at 6 months.
Highest reported target lesion primary patency at 6 months1.
Highest reported target lesion primary patency at 6 months1.
Now with proven data at 5-years. Watch the video to see the key results:
Big impact
IN.PACT™ Admiral™† for AV Fistula is a one-of-a-kind drug coated balloon that’s uniquely designed to address AV Access procedures needs:
Unique impact
Thanks to its unique drug-coated formulation, IN.PACT™ DCB (Drug-Coated Balloon) treats the causes of fistula stenosis, not just the symptoms. Combining an anti-proliferative drug and an excipient, it offers the highest reported primary patency of any DCB.1*
Lookstein RA, et al. Drug-Coated Balloons for Dysfunctional Dialysis Arteriovenous Fistulas. N Engl J Med 2020;383:733-42. DOI: 10.1056/NEJMoa1914617. Highlighted results reported at both 180 and 210 days.
Holden A., IN.PACT AV Access Trial, 3-years results. Charing Cross London 2022.
Holden A. IN.PACT AV Access Outcomes: We know which DCB to use! Presented at Charing Cross 2024.
In an AV DCB study.
The approved product name for the drug-coated balloon is IN.PACT™ Admiral™ Paclitaxel-coated PTA Balloon Catheter.